(+)-catechin multiple interactions ISO RGD:1347686 6480464 [Catechin co-treated with Grape Seed Proanthocyanidins] results in decreased expression of NANOG mRNA CTD PMID:24763279 (20S)-ginsenoside Rg3 decreases expression ISO RGD:1347686 6480464 ginsenoside Rg3 results in decreased expression of NANOG mRNA CTD PMID:31916386 (S)-naringenin decreases expression ISO RGD:1347686 6480464 naringenin results in decreased expression of NANOG protein CTD PMID:27468969 (S)-nicotine increases expression ISO RGD:1347686 6480464 Nicotine results in increased expression of NANOG mRNA, Nicotine results in increased expression of NANOG protein CTD PMID:23219715 (S)-nicotine increases expression ISO RGD:1553059 6480464 Nicotine results in increased expression of NANOG protein CTD PMID:31507073 (S)-nicotine multiple interactions ISO RGD:1347686 6480464 [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of NANOG protein, SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA] CTD PMID:23219715 , PMID:30259641 1,2-dichloroethane decreases expression ISO RGD:1553059 6480464 ethylene dichloride results in decreased expression of NANOG mRNA CTD PMID:28189721 , PMID:28960355 1,2-dimethylhydrazine multiple interactions EXP 6480464 [APC protein affects the susceptibility to 1, 2-Dimethylhydrazine] which results in decreased expression of NANOG mRNA CTD PMID:27840820 17beta-estradiol increases expression ISO RGD:1347686 6480464 Estradiol results in increased expression of NANOG protein CTD PMID:23391485 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1553059 6480464 Tetrachlorodibenzodioxin results in increased expression of NANOG mRNA CTD PMID:24058054 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO RGD:1347686 6480464 N-(2-(3H-indol-3-yl)ethyl)-9-isopropyl-2-(5-methyl-3-pyridyl)purin-6-amine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of NANOG mRNA] CTD PMID:30203000 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO RGD:1347686 6480464 Tetrachlorodibenzodioxin results in increased expression of NANOG mRNA CTD PMID:30203000 2-methoxy-17beta-estradiol multiple interactions ISO RGD:1553059 6480464 2-Methoxyestradiol inhibits the reaction [Curcumin results in increased expression of NANOG mRNA] CTD PMID:25822711 3,5,6-trichloro-2-pyridinol decreases expression ISO RGD:1553059 6480464 3 more ... CTD PMID:23220036 3,5,6-trichloropyridine-2-one decreases expression ISO RGD:1553059 6480464 3 more ... CTD PMID:23220036 3-methyladenine increases expression ISO RGD:1553059 6480464 3-methyladenine results in increased expression of NANOG mRNA CTD PMID:21681844 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one multiple interactions ISO RGD:1347686 6480464 [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of NANOG protein CTD PMID:30259641 4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one increases expression ISO RGD:1347686 6480464 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased expression of NANOG protein CTD PMID:30259641 5-aza-2'-deoxycytidine decreases expression ISO RGD:1347686 6480464 Decitabine results in decreased expression of NANOG mRNA CTD PMID:23300844 5-fluorouracil affects expression ISO RGD:1553059 6480464 Fluorouracil affects the expression of NANOG protein CTD PMID:21296659 5-fluorouracil decreases expression ISO RGD:1347686 6480464 Fluorouracil results in decreased expression of NANOG mRNA CTD PMID:24737281 ABT-737 decreases expression ISO RGD:1347686 6480464 ABT-737 results in decreased expression of NANOG protein CTD PMID:23918355 acetic acid decreases expression ISO RGD:1553059 6480464 Acetic Acid results in decreased expression of NANOG protein CTD PMID:21296659 acrylamide decreases expression EXP 6480464 Acrylamide results in decreased expression of NANOG mRNA CTD PMID:28959563 afimoxifene increases expression ISO RGD:1347686 6480464 afimoxifene results in increased expression of NANOG protein CTD PMID:27581495 all-trans-retinoic acid multiple interactions ISO RGD:1553059 6480464 NR6A1 protein affects the reaction [Tretinoin results in decreased expression of NANOG mRNA] CTD PMID:16166633 all-trans-retinoic acid multiple interactions ISO RGD:1347686 6480464 [Arsenic Trioxide co-treated with Tretinoin] results in decreased expression of NANOG protein CTD PMID:30093655 all-trans-retinoic acid affects expression ISO RGD:1347686 6480464 Tretinoin affects the expression of NANOG mRNA CTD PMID:31600526 all-trans-retinoic acid increases expression ISO RGD:1553059 6480464 Tretinoin results in increased expression of NANOG protein CTD PMID:30442713 all-trans-retinoic acid increases cleavage ISO RGD:1553059 6480464 Tretinoin results in increased cleavage of NANOG protein CTD PMID:29767511 all-trans-retinoic acid decreases expression ISO RGD:1553059 6480464 Tretinoin results in decreased expression of NANOG mRNA CTD PMID:22466603 all-trans-retinoic acid decreases expression ISO RGD:1347686 6480464 Tretinoin results in decreased expression of NANOG mRNA CTD PMID:16168501 , PMID:17138961 apigenin decreases expression ISO RGD:1347686 6480464 Apigenin results in decreased expression of NANOG protein CTD PMID:27468969 arsenous acid multiple interactions ISO RGD:1347686 6480464 [Arsenic Trioxide co-treated with Tretinoin] results in decreased expression of NANOG protein more ... CTD PMID:29396848 , PMID:30093655 arsenous acid decreases expression ISO RGD:1347686 6480464 Arsenic Trioxide results in decreased expression of NANOG mRNA CTD PMID:33634982 arsenous acid increases expression ISO RGD:1347686 6480464 Arsenic Trioxide results in increased expression of NANOG mRNA, Arsenic Trioxide results in increased expression of NANOG protein CTD PMID:29396848 arsenous acid decreases expression ISO RGD:1553059 6480464 Arsenic Trioxide results in decreased expression of NANOG mRNA CTD PMID:29767511 arsenous acid increases cleavage ISO RGD:1553059 6480464 Arsenic Trioxide results in increased cleavage of NANOG protein CTD PMID:29767511 belinostat increases expression ISO RGD:1347686 6480464 belinostat results in increased expression of NANOG mRNA CTD PMID:26272509 belinostat multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA CTD PMID:27188386 benzo[a]pyrene decreases expression ISO RGD:1347686 6480464 Benzo(a)pyrene results in decreased expression of NANOG mRNA CTD PMID:22316170 benzo[a]pyrene decreases methylation ISO RGD:1347686 6480464 Benzo(a)pyrene results in decreased methylation of NANOG 3' UTR CTD PMID:27901495 benzo[a]pyrene affects methylation ISO RGD:1347686 6480464 Benzo(a)pyrene affects the methylation of NANOG promoter CTD PMID:27901495 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1553059 6480464 Diethylhexyl Phthalate results in decreased expression of NANOG mRNA CTD PMID:28286118 bis(2-ethylhexyl) phthalate decreases expression ISO RGD:1347686 6480464 Diethylhexyl Phthalate results in decreased expression of NANOG mRNA CTD PMID:31163220 bisphenol A increases expression ISO RGD:1553059 6480464 bisphenol A results in increased expression of NANOG mRNA, bisphenol A results in increased expression of NANOG protein CTD PMID:24090592 , PMID:31288075 bisphenol A multiple interactions ISO RGD:1553059 6480464 [bisphenol A co-treated with Stigmasterol] results in decreased expression of NANOG mRNA, bisphenol A inhibits the reaction [GW 4064 results in decreased expression of NANOG mRNA] CTD PMID:30245210 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of NANOG mRNA, bisphenol A results in decreased expression of NANOG protein CTD PMID:24134786 , PMID:25181051 bisphenol A increases expression ISO RGD:1347686 6480464 bisphenol A results in increased expression of NANOG mRNA, bisphenol A results in increased expression of NANOG protein CTD PMID:23391485 , PMID:24424067 bromochloroacetic acid increases expression ISO RGD:1553059 6480464 bromochloroacetic acid results in increased expression of NANOG protein CTD PMID:21296659 butanal decreases expression ISO RGD:1347686 6480464 butyraldehyde results in decreased expression of NANOG mRNA CTD PMID:26079696 cadmium atom decreases expression ISO RGD:1347686 6480464 Cadmium results in decreased expression of NANOG mRNA CTD PMID:24376830 carboplatin increases expression ISO RGD:1347686 6480464 Carboplatin results in increased expression of NANOG mRNA CTD PMID:25605917 casticin decreases expression ISO RGD:1347686 6480464 casticin results in decreased expression of NANOG mRNA CTD PMID:32268151 casticin multiple interactions ISO RGD:1347686 6480464 casticin promotes the reaction [MIR148A mRNA results in decreased expression of NANOG mRNA] more ... CTD PMID:32268151 CHIR 99021 decreases expression ISO RGD:1347686 6480464 Chir 99021 results in decreased expression of NANOG mRNA CTD PMID:31711903 CHIR-98014 decreases expression ISO RGD:1347686 6480464 Chir 98014 results in decreased expression of NANOG mRNA CTD PMID:22723015 chlordecone increases expression ISO RGD:1553059 6480464 Chlordecone results in increased expression of NANOG mRNA CTD PMID:33711761 chlorpromazine decreases expression ISO RGD:1347686 6480464 Chlorpromazine results in decreased expression of NANOG mRNA CTD PMID:30703373 chlorpyrifos decreases expression ISO RGD:1553059 6480464 Chlorpyrifos results in decreased expression of NANOG mRNA CTD PMID:23220036 chromium(6+) increases expression ISO RGD:1553059 6480464 chromium hexavalent ion results in increased expression of NANOG mRNA CTD PMID:19654923 chromium(6+) multiple interactions ISO RGD:1553059 6480464 MAP2K7 protein promotes the reaction [chromium hexavalent ion results in increased expression of NANOG mRNA] CTD PMID:19654923 ciprofloxacin increases expression ISO RGD:1347686 6480464 Ciprofloxacin results in increased expression of NANOG protein CTD PMID:26947806 cisplatin multiple interactions ISO RGD:1347686 6480464 [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG mRNA more ... CTD PMID:20705681 more ... cisplatin decreases expression ISO RGD:1347686 6480464 Cisplatin results in decreased expression of NANOG mRNA CTD PMID:23300844 cisplatin increases expression ISO RGD:1347686 6480464 Cisplatin results in increased expression of NANOG mRNA, Cisplatin results in increased expression of NANOG protein CTD PMID:21618587 cobalt dichloride multiple interactions ISO RGD:1347686 6480464 [EPAS1 protein results in increased susceptibility to cobaltous chloride] which results in increased expression of NANOG mRNA, [HIF1A protein results in increased susceptibility to cobaltous chloride] which results in increased expression of NANOG mRNA CTD PMID:25805230 crocidolite asbestos increases expression ISO RGD:1553059 6480464 Asbestos, Crocidolite results in increased expression of NANOG mRNA CTD PMID:29279043 curcumin multiple interactions ISO RGD:1553059 6480464 2-methoxyestradiol inhibits the reaction [Curcumin results in increased expression of NANOG mRNA] CTD PMID:25822711 curcumin increases expression ISO RGD:1553059 6480464 Curcumin results in increased expression of NANOG mRNA, Curcumin results in increased expression of NANOG protein CTD PMID:25822711 , PMID:27237783 cypermethrin increases expression ISO RGD:1553059 6480464 cypermethrin results in increased expression of NANOG mRNA CTD PMID:32214279 decabromodiphenyl ether decreases expression ISO RGD:1347686 6480464 decabromobiphenyl ether results in decreased expression of NANOG mRNA CTD PMID:26206603 deoxycholic acid increases expression ISO RGD:1553059 6480464 Deoxycholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 diallyl trisulfide decreases expression ISO RGD:1347686 6480464 diallyl trisulfide results in decreased expression of NANOG protein CTD PMID:29626521 diallyl trisulfide multiple interactions ISO RGD:1347686 6480464 diallyl trisulfide inhibits the reaction [CTNNB1 protein results in increased expression of NANOG protein] CTD PMID:29626521 diarsenic trioxide multiple interactions ISO RGD:1347686 6480464 [Arsenic Trioxide co-treated with Tretinoin] results in decreased expression of NANOG protein more ... CTD PMID:29396848 , PMID:30093655 diarsenic trioxide decreases expression ISO RGD:1347686 6480464 Arsenic Trioxide results in decreased expression of NANOG mRNA CTD PMID:33634982 diarsenic trioxide increases cleavage ISO RGD:1553059 6480464 Arsenic Trioxide results in increased cleavage of NANOG protein CTD PMID:29767511 diarsenic trioxide decreases expression ISO RGD:1553059 6480464 Arsenic Trioxide results in decreased expression of NANOG mRNA CTD PMID:29767511 diarsenic trioxide increases expression ISO RGD:1347686 6480464 Arsenic Trioxide results in increased expression of NANOG mRNA, Arsenic Trioxide results in increased expression of NANOG protein CTD PMID:29396848 dieldrin multiple interactions ISO RGD:1347686 6480464 Dieldrin inhibits the reaction [[4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in decreased expression of NANOG mRNA] CTD PMID:32949729 dimethyl sulfoxide decreases expression ISO RGD:1347686 6480464 Dimethyl Sulfoxide results in decreased expression of NANOG mRNA CTD PMID:22105179 dioxygen multiple interactions ISO RGD:1553059 6480464 Oxygen deficiency promotes the reaction [LIF protein affects the reaction NANOG mRNA] CTD PMID:26723917 disodium selenite decreases expression ISO RGD:1347686 6480464 Sodium Selenite results in decreased expression of NANOG mRNA CTD PMID:18175754 dorsomorphin multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 entinostat increases expression ISO RGD:1347686 6480464 entinostat results in increased expression of NANOG mRNA CTD PMID:26272509 entinostat multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA CTD PMID:27188386 ethanol increases expression EXP 6480464 Ethanol results in increased expression of NANOG mRNA CTD PMID:29769550 ethanol increases expression ISO RGD:1347686 6480464 Ethanol results in increased expression of NANOG mRNA CTD PMID:23378141 fluoxetine affects expression ISO RGD:1553059 6480464 Fluoxetine affects the expression of NANOG mRNA CTD PMID:29893963 folic acid increases expression ISO RGD:1553059 6480464 Folic Acid results in increased expression of NANOG mRNA CTD PMID:25629700 fulvestrant increases expression ISO RGD:1347686 6480464 fulvestrant results in increased expression of NANOG protein CTD PMID:27581495 furan decreases expression EXP 6480464 furan results in decreased expression of NANOG mRNA CTD PMID:25539665 gemcitabine decreases expression ISO RGD:1347686 6480464 gemcitabine results in decreased expression of NANOG mRNA CTD PMID:25605917 GW 4064 decreases expression ISO RGD:1553059 6480464 GW 4064 results in decreased expression of NANOG mRNA CTD PMID:30245210 GW 4064 multiple interactions ISO RGD:1553059 6480464 bisphenol A inhibits the reaction [GW 4064 results in decreased expression of NANOG mRNA], Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of NANOG mRNA] CTD PMID:30245210 heptachlor multiple interactions ISO RGD:1347686 6480464 Heptachlor inhibits the reaction [[4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in decreased expression of NANOG mRNA] CTD PMID:32949729 hexachlorophene multiple interactions ISO RGD:1347686 6480464 Hexachlorophene inhibits the reaction [[4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in decreased expression of NANOG mRNA] CTD PMID:32949729 indometacin decreases expression ISO RGD:1347686 6480464 Indomethacin results in decreased expression of NANOG mRNA CTD PMID:24737281 ivermectin decreases expression ISO RGD:1347686 6480464 Ivermectin results in decreased expression of NANOG mRNA, Ivermectin results in decreased expression of NANOG protein CTD PMID:29257278 kaempferol increases expression ISO RGD:1553059 6480464 kaempferol results in increased expression of NANOG protein CTD PMID:26683311 lead diacetate decreases expression ISO RGD:1553059 6480464 lead acetate results in decreased expression of NANOG mRNA CTD PMID:25270620 lead diacetate increases expression ISO RGD:1553059 6480464 lead acetate results in increased expression of NANOG mRNA CTD PMID:31715224 limonin decreases expression ISO RGD:1347686 6480464 limonin results in decreased expression of NANOG mRNA, limonin results in decreased expression of NANOG protein CTD PMID:30738134 lipopolysaccharide multiple interactions EXP 6480464 NANOG inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] more ... CTD PMID:22200792 lithium chloride increases expression ISO RGD:1347686 6480464 Lithium Chloride results in increased expression of NANOG mRNA CTD PMID:20069066 lithium chloride multiple interactions ISO RGD:1347686 6480464 SFRP2 protein affects the reaction [Lithium Chloride results in increased expression of NANOG mRNA] CTD PMID:20069066 lupeol decreases expression ISO RGD:1553059 6480464 lupeol results in decreased expression of NANOG protein CTD PMID:20979057 LY294002 multiple interactions ISO RGD:1553059 6480464 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with sodium arsenite] results in decreased expression of NANOG protein CTD PMID:23143138 LY294002 decreases expression ISO RGD:1553059 6480464 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of NANOG protein CTD PMID:23143138 methylmercury chloride increases expression ISO RGD:1347686 6480464 methylmercuric chloride results in increased expression of NANOG mRNA CTD PMID:22555245 , PMID:23903816 methylparaben increases expression ISO RGD:1347686 6480464 methylparaben results in increased expression of NANOG mRNA, methylparaben results in increased expression of NANOG protein CTD PMID:27581495 N-acetyl-L-cysteine multiple interactions ISO RGD:1347686 6480464 Acetylcysteine inhibits the reaction [Particulate Matter results in decreased expression of NANOG protein] CTD PMID:32745510 N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal multiple interactions ISO RGD:1347686 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of NANOG protein] CTD PMID:23651583 nicotine increases expression ISO RGD:1347686 6480464 Nicotine results in increased expression of NANOG mRNA, Nicotine results in increased expression of NANOG protein CTD PMID:23219715 nicotine increases expression ISO RGD:1553059 6480464 Nicotine results in increased expression of NANOG protein CTD PMID:31507073 nicotine multiple interactions ISO RGD:1347686 6480464 [Nicotine co-treated with 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone] results in increased expression of NANOG protein, SNAI1 mutant form inhibits the reaction [Nicotine results in increased expression of NANOG mRNA] CTD PMID:23219715 , PMID:30259641 nocodazole decreases expression ISO RGD:1347686 6480464 Nocodazole results in decreased expression of NANOG protein CTD PMID:21559451 Nonylphenol increases expression ISO RGD:1553059 6480464 nonylphenol results in increased expression of NANOG mRNA CTD PMID:31288075 paclitaxel multiple interactions ISO RGD:1347686 6480464 [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG mRNA, [Cisplatin co-treated with Paclitaxel] results in increased expression of NANOG protein CTD PMID:20705681 panobinostat increases expression ISO RGD:1347686 6480464 panobinostat results in increased expression of NANOG mRNA CTD PMID:26272509 panobinostat multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA CTD PMID:27188386 perfluorooctane-1-sulfonic acid decreases expression ISO RGD:1553059 6480464 perfluorooctane sulfonic acid results in decreased expression of NANOG mRNA, perfluorooctane sulfonic acid results in decreased expression of NANOG protein CTD PMID:24098361 perfluorooctane-1-sulfonic acid increases expression ISO RGD:1347686 6480464 perfluorooctane sulfonic acid results in increased expression of NANOG protein CTD PMID:27153767 perfluorooctane-1-sulfonic acid increases expression ISO RGD:1553059 6480464 perfluorooctane sulfonic acid results in increased expression of NANOG mRNA, perfluorooctane sulfonic acid results in increased expression of NANOG protein CTD PMID:25510869 perfluorooctanoic acid increases expression ISO RGD:1347686 6480464 perfluorooctanoic acid results in increased expression of NANOG protein CTD PMID:27153767 permethrin multiple interactions ISO RGD:1347686 6480464 Permethrin promotes the reaction [[4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in decreased expression of NANOG mRNA] CTD PMID:32949729 pirinixic acid decreases expression ISO RGD:1553059 6480464 pirinixic acid results in decreased expression of NANOG mRNA CTD PMID:25270620 quercetin decreases expression ISO RGD:1347686 6480464 Quercetin results in decreased expression of NANOG protein CTD PMID:22422628 more ... resveratrol decreases expression ISO RGD:1347686 6480464 resveratrol results in decreased expression of NANOG mRNA, resveratrol results in decreased expression of NANOG protein CTD PMID:21304978 more ... resveratrol decreases response to substance ISO RGD:1347686 6480464 NANOG protein results in decreased susceptibility to resveratrol CTD PMID:21304978 resveratrol multiple interactions ISO RGD:1347686 6480464 benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [resveratrol results in decreased expression of NANOG protein], TP53 mutant form inhibits the reaction [resveratrol results in decreased expression of NANOG protein] CTD PMID:23651583 rotenone multiple interactions ISO RGD:1347686 6480464 Rotenone inhibits the reaction [[4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide co-treated with LDN 193189] results in decreased expression of NANOG mRNA] CTD PMID:32949729 rotenone decreases expression ISO RGD:1347686 6480464 Rotenone results in decreased expression of NANOG mRNA CTD PMID:33512557 SB 431542 multiple interactions ISO RGD:1347686 6480464 [4-(5-benzo(1 more ... CTD PMID:27188386 , PMID:32949729 sirolimus increases expression ISO RGD:1553059 6480464 Sirolimus results in increased expression of NANOG mRNA CTD PMID:21681844 sodium arsenite multiple interactions ISO RGD:1347686 6480464 monoisoamyl-2, 3-dimercaptosuccinate inhibits the reaction [sodium arsenite results in decreased expression of NANOG mRNA] CTD PMID:19615344 sodium arsenite affects expression ISO RGD:1553059 6480464 sodium arsenite affects the expression of NANOG mRNA CTD PMID:28370166 sodium arsenite affects expression ISO RGD:1347686 6480464 sodium arsenite affects the expression of NANOG mRNA CTD PMID:29301061 sodium arsenite increases expression ISO RGD:1553059 6480464 sodium arsenite results in increased expression of NANOG mRNA, sodium arsenite results in increased expression of NANOG protein CTD PMID:22641621 , PMID:26438402 sodium arsenite decreases expression ISO RGD:1553059 6480464 sodium arsenite results in decreased expression of NANOG protein CTD PMID:23143138 , PMID:23219847 sodium arsenite multiple interactions ISO RGD:1553059 6480464 [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with sodium arsenite] results in decreased expression of NANOG protein, [OGG1 gene mutant form results in increased susceptibility to sodium arsenite] which affects the expression of NANOG mRNA CTD PMID:23143138 , PMID:26438402 sodium arsenite increases expression ISO RGD:1347686 6480464 sodium arsenite results in increased expression of NANOG mRNA CTD PMID:24431212 , PMID:31120745 sodium arsenite decreases expression ISO RGD:1347686 6480464 sodium arsenite results in decreased expression of NANOG mRNA, sodium arsenite results in decreased expression of NANOG protein CTD PMID:19615344 more ... sodium chlorate increases expression ISO RGD:1553059 6480464 sodium chlorate results in increased expression of NANOG mRNA CTD PMID:19937756 stigmasterol decreases expression ISO RGD:1553059 6480464 Stigmasterol results in decreased expression of NANOG mRNA CTD PMID:30245210 stigmasterol multiple interactions ISO RGD:1553059 6480464 [bisphenol A co-treated with Stigmasterol] results in decreased expression of NANOG mRNA, Stigmasterol inhibits the reaction [GW 4064 results in decreased expression of NANOG mRNA] CTD PMID:30245210 sunitinib increases expression ISO RGD:1347686 6480464 sunitinib results in increased expression of NANOG mRNA CTD PMID:25605917 sunitinib decreases expression ISO RGD:1347686 6480464 Sunitinib results in decreased expression of NANOG mRNA CTD PMID:31533062 Tanshinone I increases expression ISO RGD:1553059 6480464 tanshinone results in increased expression of NANOG mRNA CTD PMID:25186638 Tanshinone I multiple interactions EXP 6480464 tanshinone inhibits the reaction [Estrogens deficiency results in decreased expression of NANOG protein] CTD PMID:31108107 taurocholic acid increases expression ISO RGD:1553059 6480464 Taurocholic Acid results in increased expression of NANOG mRNA CTD PMID:27151938 thalidomide decreases expression ISO RGD:1553059 6480464 Thalidomide results in decreased expression of NANOG mRNA CTD PMID:26217789 thymoquinone decreases expression ISO RGD:1347686 6480464 thymoquinone results in decreased expression of NANOG protein CTD PMID:31298468 titanium dioxide increases expression ISO RGD:1553059 6480464 titanium dioxide results in increased expression of NANOG mRNA CTD PMID:29264374 trichostatin A increases expression ISO RGD:1347686 6480464 trichostatin A results in increased expression of NANOG mRNA CTD PMID:22723015 more ... trichostatin A multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA CTD PMID:27188386 triclosan decreases expression ISO RGD:1553059 6480464 Triclosan results in decreased expression of NANOG mRNA, Triclosan results in decreased expression of NANOG protein CTD PMID:24879426 urethane decreases expression ISO RGD:1347686 6480464 Urethane results in decreased expression of NANOG mRNA CTD PMID:28818685 valproic acid increases expression ISO RGD:1347686 6480464 Valproic Acid results in increased expression of NANOG mRNA CTD PMID:22723015 more ... valproic acid decreases expression ISO RGD:1347686 6480464 Valproic Acid results in decreased expression of NANOG mRNA CTD PMID:23179753 more ... valproic acid multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 , PMID:32949729 vorinostat decreases expression ISO RGD:1347686 6480464 vorinostat results in decreased expression of NANOG mRNA CTD PMID:27188386 vorinostat multiple interactions ISO RGD:1347686 6480464 [NOG protein co-treated with Vorinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA CTD PMID:27188386 vorinostat increases expression ISO RGD:1347686 6480464 vorinostat results in increased expression of NANOG mRNA CTD PMID:26272509
